Alzheimer's disease risk gene cd33 inhibits microglial uptake of amyloid beta

Neuron

Volumn 78, Issue 4, 2013, Pages 631-643

  Griciuc, Ana ^a   Serrano Pozo, Alberto ^a   Parrado, Antonio R ^a   Lesinski, Andrea N ^a   Asselin, Caroline N ^a   Mullin, Kristina ^a   Hooli, Basavaraj ^a   Choi, SeHoon ^a   Hyman, Bradley T ^a   Tanzi, Rudolph E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CD33 ANTIGEN;

ALLELE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD33 GENE; CELL COUNT; CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FRONTAL CORTEX; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SINGLE NUCLEOTIDE POLYMORPHISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MATCHED-PAIR ANALYSIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROGLIA; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; RNA, MESSENGER; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84878433339     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2013.04.014     Document Type: Article

References (57)

1. Aguzzi A., Barres B.A., Bennett M.L. Microglia: scapegoat, saboteur, or something else?. Science 2013, 339:156-161.
2. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J.Cereb. Blood Flow Metab. 2007, 27:909-918.
3. Bertram L., Lange C., Mullin K., Parkinson M., Hsiao M., Hogan M.F., Schjeide B.M., Hooli B., Divito J., Ionita I., et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am. J. Hum. Genet. 2008, 83:623-632.
4. Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron 2010, 68:270-281.
5. Brinkman-Van der Linden E.C., Angata T., Reynolds S.A., Powell L.D., Hedrick S.M., Varki A. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol. Cell. Biol. 2003, 23:4199-4206.
6. Chan S.L., Kim W.S., Kwok J.B., Hill A.F., Cappai R., Rye K.A., Garner B. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein invitro. J.Neurochem. 2008, 106:793-804.
7. Choi S.H., Veeraraghavalu K., Lazarov O., Marler S., Ransohoff R.M., Ramirez J.M., Sisodia S.S. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 2008, 59:568-580.
8. Crocker P.R., Paulson J.C., Varki A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 2007, 7:255-266.
9. Crocker P.R., McMillan S.J., Richards H.E. CD33-related siglecs as potential modulators of inflammatory responses. Ann. N Y Acad. Sci. 2012, 1253:102-111.
10. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., Holtzman D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism invivo. Neuron 2004, 41:193-202.
11. Frank S., Burbach G.J., Bonin M., Walter M., Streit W., Bechmann I., Deller T. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 2008, 56:1438-1447.
12. Gorlovoy P., Larionov S., Pham T.T., Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 2009, 23:2502-2513.
13. Grathwohl S.A., Kälin R.E., Bolmont T., Prokop S., Winkelmann G., Kaeser S.A., Odenthal J., Radde R., Eldh T., Gandy S., et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci. 2009, 12:1361-1363.
14. Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. TREM2 variants in Alzheimer's disease. N.Engl. J. Med. 2013, 368:117-127. Alzheimer Genetic Analysis Group.
15. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
16. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
17. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
18. Hashimoto T., Serrano-Pozo A., Hori Y., Adams K.W., Takeda S., Banerji A.O., Mitani A., Joyner D., Thyssen D.H., Bacskai B.J., et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J.Neurosci. 2012, 32:15181-15192.
19. Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J.C., Carrasquillo M.M., Abraham R., Hamshere M.L., Pahwa J.S., Moskvina V., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43:429-435. Alzheimer's Disease Neuroimaging Initiative, CHARGE consortiumCHARGE consortium, EADI1 consortiumEADI1 consortium.
20. Hoyer J.D., Grogg K.L., Hanson C.A., Gamez J.D., Dogan A. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. Am. J. Clin. Pathol. 2008, 129:316-323.
21. Hsieh C.L., Koike M., Spusta S.C., Niemi E.C., Yenari M., Nakamura M.C., Seaman W.E. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J.Neurochem. 2009, 109:1144-1156.
22. Jandus C., Simon H.U., von Gunten S. Targeting siglecs-a novel pharmacological strategy for immuno- and glycotherapy. Biochem. Pharmacol. 2011, 82:323-332.
23. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide invivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13:159-170.
24. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
25. Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N.Engl. J. Med. 2013, 368:107-116.
26. Jurcic J.G. What happened to anti-CD33 therapy for acute myeloid leukemia?. Curr Hematol Malig Rep 2012, 7:65-73.
27. Karch C.M., Jeng A.T., Nowotny P., Cady J., Cruchaga C., Goate A.M. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS ONE 2012, 7:e50976.
28. Klesney-Tait J., Turnbull I.R., Colonna M. The TREM receptor family and signal integration. Nat. Immunol. 2006, 7:1266-1273.
29. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099. European Alzheimer's Disease Initiative Investigators.
30. Lee C.Y., Tse W., Smith J.D., Landreth G.E. Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels. J.Biol. Chem. 2012, 287:2032-2044.
31. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9:184.
32. Mandrekar S., Jiang Q., Lee C.Y., Koenigsknecht-Talboo J., Holtzman D.M., Landreth G.E. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J.Neurosci. 2009, 29:4252-4262.
33. Melchior B., Garcia A.E., Hsiung B.K., Lo K.M., Doose J.M., Thrash J.C., Stalder A.K., Staufenbiel M., Neumann H., Carson M.J. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2010, 2:e00037.
34. Naj A.C., Jun G., Beecham G.W., Wang L.S., Vardarajan B.N., Buros J., Gallins P.J., Buxbaum J.D., Jarvik G.P., Crane P.K., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43:436-441.
35. O'Reilly M.K., Paulson J.C. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 2009, 30:240-248.
36. Paulson J.C., Macauley M.S., Kawasaki N. Siglecs as sensors of self in innate and adaptive immune responses. Ann. N Y Acad. Sci. 2012, 1253:37-48.
37. Pérez-Oliva A.B., Martínez-Esparza M., Vicente-Fernández J.J., Corral-San Miguel R., García-Peñarrubia P., Hernández-Caselles T. Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells. Glycobiology 2011, 21:757-770.
38. Pillai S., Netravali I.A., Cariappa A., Mattoo H. Siglecs and immune regulation. Annu. Rev. Immunol. 2012, 30:357-392.
39. Prinz M., Priller J., Sisodia S.S., Ransohoff R.M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 2011, 14:1227-1235.
40. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
41. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N.Engl. J. Med. 2010, 362:329-344.
42. R Development Core Team (2009). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. ISBN 3-900051-07-0, . http://www.R-project.org.
43. Reilly J.F., Games D., Rydel R.E., Freedman S., Schenk D., Young W.G., Morrison J.H., Bloom F.E. Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc. Natl. Acad. Sci. USA 2003, 100:4837-4842.
44. Ricart A.D. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 2011, 17:6417-6427.
45. Rollins-Raval M.A., Roth C.G. The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias. Histopathology 2012, 60:933-942.
46. Selkoe D.J. Preventing Alzheimer's disease. Science 2012, 337:1488-1492.
47. Serrano-Pozo A., Mielke M.L., Gomez-Isla T., Betensky R.A., Growdon J.H., Frosch M.P., Hyman B.T. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am. J. Pathol. 2011, 179:1373-1384.
48. Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C., et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840. CHARGE Consortium, GERAD1 ConsortiumGERAD1 Consortium, EADI1 ConsortiumEADI1 Consortium.
49. Shen G.Q., Abdullah K.G., Wang Q.K. The TaqMan method for SNP genotyping. Methods Mol. Biol. 2009, 578:293-306.
50. Tanzi R.E. A brief history of Alzheimer's disease gene discovery. J.Alzheimers Dis. 2013, 33(Suppl 1):S5-S13.
51. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
52. Treusch S., Hamamichi S., Goodman J.L., Matlack K.E., Chung C.Y., Baru V., Shulman J.M., Parrado A., Bevis B.J., Valastyan J.S., et al. Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 2011, 334:1241-1245.
53. von Gunten S., Bochner B.S. Basic and clinical immunology of Siglecs. Ann. N Y Acad. Sci. 2008, 1143:61-82.
54. Walter R.B., Häusermann P., Raden B.W., Teckchandani A.M., Kamikura D.M., Bernstein I.D., Cooper J.A. Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor. Traffic 2008, 9:267-279.
55. Wang Y.J., Wang X., Lu J.J., Li Q.X., Gao C.Y., Liu X.H., Sun Y., Yang M., Lim Y., Evin G., et al. p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. J.Neurosci. 2011, 31:2292-2304.
56. Xiao Q., Gil S.C., Yan P., Wang Y., Han S., Gonzales E., Perez R., Cirrito J.R., Lee J.M. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J.Biol. Chem. 2012, 287:21279-21289.
57. Yerbury J.J., Poon S., Meehan S., Thompson B., Kumita J.R., Dobson C.M., Wilson M.R. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007, 21:2312-2322.